This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
Azeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (34.4m).
GHO Capital raises 975m in largest ever European private equity healthcare fund.
Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.
Danish Novo Nordisk A/S has secured access to Dicerna Incs GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.
Europe’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.
Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AGs anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).
Autoimmunity specialist SciRhom GmbH has kicked of a first-in-class antibody development programme targeting iRhom2.